Contineum Therapeutics, Inc. (CTNM) on Thursday announced positive topline data from its PIPE-791 Phase 1b positron emission tomography (PET) trial, which met its primary endpoint.
The Phase 1b study was designed to assess the correlation between pharmacokinetics and lysophosphatidic acid 1 (LPA1) receptor occupancy using PET imaging in healthy volunteers, as well as in patients with idiopathic pulmonary fibrosis or progressive multiple sclerosis.
The trial met its primary objectives, demonstrating that PIPE-791 achieved high brain receptor occupancy in healthy volunteers and progressive multiple sclerosis patients, with a clear pharmacokinetic correlation between drug exposure and receptor engagement.
PIPE-791 also showed a safety and tolerability profile consistent with the company's previous clinical studies.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.